Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H16N2O.ClH |
| Molecular Weight | 264.751 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=C(CC2=NCCN2)C3=C(O1)C=CC=C3
InChI
InChIKey=YDDYHDKRIBOHOT-UHFFFAOYSA-N
InChI=1S/C14H16N2O.ClH/c1-2-12-11(9-14-15-7-8-16-14)10-5-3-4-6-13(10)17-12;/h3-6H,2,7-9H2,1H3,(H,15,16);1H
Coumazoline is a vasoconstrictor developed as a nasal decongestant by a French corporation Labez. Intravenous administration of the compound to dogs lead to a marked and prolonged drop in the temperature of the gingival mucosa. In rats, coumazoline caused slowing of the dye diffusion on the surface of the skin. The compound did not influence the ciliary motility, as was measured on an isolated guinea pig trachea.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16205103
Created by
admin on Mon Mar 31 18:03:02 GMT 2025 , Edited by admin on Mon Mar 31 18:03:02 GMT 2025
|
PRIMARY | |||
|
253-670-3
Created by
admin on Mon Mar 31 18:03:02 GMT 2025 , Edited by admin on Mon Mar 31 18:03:02 GMT 2025
|
PRIMARY | |||
|
37795-09-8
Created by
admin on Mon Mar 31 18:03:02 GMT 2025 , Edited by admin on Mon Mar 31 18:03:02 GMT 2025
|
PRIMARY | |||
|
DTXSID20958837
Created by
admin on Mon Mar 31 18:03:02 GMT 2025 , Edited by admin on Mon Mar 31 18:03:02 GMT 2025
|
PRIMARY | |||
|
U3P3Y52JKX
Created by
admin on Mon Mar 31 18:03:02 GMT 2025 , Edited by admin on Mon Mar 31 18:03:02 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
